

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

FEB 28 2005

(use as many sheets as necessary)

Complete if Known

Application Number	10/623,464
Filing Date	July 18, 2003
First Named Inventor	Deh-Ming Chang
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	411-000100US
Date Submitted	February 25, 2005

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
V	01	5,824,313		Daynes et al.	10-20-1998	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
V	02	NORTON et al., Administration of dehydroepiandrosterone sulfate retards onset but not progression of autoimmune disease on NZB/W mice. Database CAPLUS, AN 1998:256302, abstract, Autoimmunity, 1997, Vol. 26(3), Pages 161-171, see abstract.	
V	03	SPENCER et al., Dysregulation of IL-10 production with aging: possible linkage to the age-associated decline in DHEA and its sulfated derivative. Database CAPLUS, AN 1996:433492, abstract, Experimental Gerontology, 1996, Vol. 31(3), Pages 393-408, see abstract.	
V	04	INSERRA et al., Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice. Database CAPLUS, AN 1998:275844, abstract, Proceedings of the Society for Experimental Biology and Medicine, 1998, Vol. 218(1), Pages 76-82.	

Examiner
SignatureDate
Considered



*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT APR 02 2004 (use as many sheets as necessary)	Complete if Known	
	Application Number	10/623,464
	Filing Date	July 18, 2003
	First Named Inventor	Deh-Ming Chang
	Group Art Unit	1645
	Examiner Name	Unassigned
	Attorney Docket Number	411-000100US
Date Submitted	March 31, 2004	


U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	01	4,366,241		Tom et al.	12-28-1982	
	02	4,376,110		David et al.	03-08-1983	
	03	4,517,288		Giegel et al.	05-14-1985	
	04	4,837,168		de Jaeger et al.	06-06-1989	
	05	6,552,010	B1	Schwartz et al.	04-22-2003	
	06	6,605,591	B1	Schwartz	08-12-2003	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	07	WO	00/54763	A2	Genelabs Technologies, Inc.	09-21-2000		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T		
	08	al-Janadi, et al., <u>J. Clin. Immunol.</u> , 1993(13):58-67.			
	09	Anaya, et al., <u>J. Rheuma.</u> , 2002, 29(9):1874-1876.			
	10	Araghi-Niknam, et al., <u>Proc. Soc. Exp. Biol. Med.</u> , 1997, 216:386-91.			
	11	Badou, et al., <u>J. Virology</u> , 2000, 74(22):10551-10562.			
	12	Bombardier, et al., <u>Arthritis Rheum.</u> , 1992, 35:630-40.			
	13	Chang, et al., <u>Arthritis Rheum.</u> , 2002, 46(11):2924-27.			
	14	Cortes, et al., <u>Blood</u> , 1995, 85(9):2516-2520.			
	15	Daynes, et al., <u>Eur. J. Immunol.</u> , 1990, 20:793-802.			
	16	Ebeling, et al., <u>Lancet</u> , 1994 (343):1479-81.			
	17	Fayad, et al., <u>Blood</u> , 2001, 97(1):256-263.			
	18	Gordon, et al., <u>Cytokine</u> , 2001, 16(5):178-86.			
	Examiner Signature			Date Considered	6/4/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT 	Complete if Known	
	Application Number	10/623,464
	Filing Date	July 18, 2003
	First Named Inventor	Deh-Ming Chang
	Group Art Unit	1645
	Examiner Name	Unassigned
	Attorney Docket Number	411-000100US
Date Submitted	March 31, 2004	

19	Hagiwara, et al., <u>Arthritis Rheum.</u> , 1996, 39:379-385.	
20	Handwerger, et al., <u>Springer Semin. Immunopathol.</u> , 1994, 16:153-80.	
21	Houssiau, et al., <u>Lupus</u> , 1995, 4:393-395.	
22	Isomäki, et al., <u>Arthritis Rheum.</u> , 1996, 39(3):386-395.	
23	Labrie, et al., <u>Ann. N.Y. Acad. Sci.</u> , 1995, (774):16-28.	
24	Lacki, et al., <u>Clinical Rheumatology</u> , 1997, 16(3):275-278.	
25	Liang, et al., <u>Arthritis Rheum.</u> , 1989, 32:1107-18.	
26	Linker-Israeli, et al., <u>J. Immunol.</u> , 1991, 147:117-23.	
27	Llorente, et al., <u>Eur. Cytokine Netw.</u> , 1993, 4:421-30.	
28	Llorente, et al., <u>Arthritis Rheum.</u> , 1994, 37(11):1647-1655.	
29	Llorente, et al., <u>Arthritis Rheum.</u> , 2000, 43(8):1790-1800.	
30	Lucas, et al., <u>J. Clin. Invest.</u> , 1985, 75:2091-93.	
31	Mease, et al., <u>Arthritis Rheum.</u> , 2000, 43(Suppl. 1):S271.	
32	Melez, et al., <u>Arthritis Rheum.</u> , 1980, 23:41-7.	
33	Mund, et al., <u>JAMA</u> , 1963, 183:917-20.	
34	Nunnari, et al., <u>Ann. Intern. Med.</u> , 2003, 139(1):26-30.	
35	Park, et al., <u>Clin. Exp. Rheumatol.</u> , 1998, 16(3):283-8.	
36	Parker, <u>Endocrinol. Metab. Clin. North Am.</u> , 1991 20:401-21.	
37	Perrier, et al., <u>J. Rheumatol.</u> , 2000, 27:935-9.	
38	Petri, et al., <u>Arthritis Rheum.</u> , 2002 (46):1820-9.	
39	Petri, et al., <u>Rheumatology</u> , 2003:42(Suppl. 1):19.	
40	Petri, et al., <u>Arthritis Rheum.</u> 1991, 34:1538-45.	
41	Richaud-Patin, et al., <u>Rev. Invest. Clin.</u> , 1995, 47:267-72.	
42	Roubinian, et al., <u>Arthritis Rheum.</u> , 1979, 22:1162-69.	
43	Straub, et al., <u>J. Clin. Endocrinol. Metab.</u> , 1998, 83:2012-17.	
44	Suzuki, et al., <u>Clin. Immunol. Immunopathol.</u> , 1991, 61:202-11.	
45	Tabata, et al., <u>Arch. Dermatol. Res.</u> , 1997, 289:410-14.	
46	Takemura, et al., <u>Virchows Archiv.</u> , 1994(424):459-64.	


Examiner Signature		Date Considered	6/4/06
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/623,464
	Filing Date	July 18, 2003
	First Named Inventor	Deh-Ming Chang
	Group Art Unit	1645
	Examiner Name	Unassigned
	Attorney Docket Number	411-000100US
Date Submitted	March 31, 2004	

47	Tan, et al., <u>Arthritis Rheum.</u> , 1982, 25:1271-77.	
48	van Vollenhoven, et al., <u>Arthritis Rheum.</u> , 1994(37):1305-10.	
49	van Vollenhoven, et al., <u>Arthritis Rheum.</u> , 1995(38):1826-31.	
50	Zietz, et al., <u>J. Rheumatol.</u> , 2000, 27:911-8.	

Examiner Signature		Date Considered	6/4/06
-----------------------	---	--------------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.